Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JPA Leaders Exchange Opinions with New Health Minister
September 17, 2007
- BUSINESS NEWS IN BRIEF
September 17, 2007
- JPA Would Like to Expand the Role of Pharmacists
September 17, 2007
- No Reduction in Technical Fees Considered: New Health Minister
September 17, 2007
- Med. Fee Curtailment Policy Caused Collapse of Med. Insurance System: 3 Social Insurance Unions
September 17, 2007
- Korosho to Shift Priority from Treatment of ADRs to Prevention
September 17, 2007
- TOPICS／JADEC, sanofi-aventis Hold HbA1c Awareness Promotion Campaign
September 17, 2007
- Use e-Details to Enhance QOV: Mr Takuma of CareNet
September 17, 2007
- Japan's First New-Type Influenza Vaccines Recommended for Approval
September 17, 2007
- SURVEY／Antirheumatic Drug Market Grew by 49% in 2006: Fuji Keizai Databook
September 17, 2007
- GENERICS NEWS IN BRIEF
September 17, 2007
- EFPIA Appreciates 20% Increase in Budget Request for Innovation
September 17, 2007
- Lundbeck, Takeda Tie Up to Develop Drugs for Mood and Anxiety Disorders
September 17, 2007
- CSL Behring Is Discriminated Against in Japan: President Mr Turner
September 17, 2007
- REGULATORY NEWS IN BRIEF
September 17, 2007
- SymBio Acquires Worldwide Rights to PEG-ZnPP
September 17, 2007
- POTELLIGENT the Most Important Technology Kyowa Hakko Has Developed in the Last 20 Years: Dr Shitara
September 17, 2007
- Eisai Ties Up with Salix to Copromote COLAZAL in the US
September 17, 2007
- Bayer to Close Its Kobe Research Center for Regenerative Medicine
September 17, 2007
- GSK to Independently Market Zantac
September 17, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…